SMSergei V. Mordanov

Sergei V. Mordanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergei V. Mordanov has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Genetic and Biochemical Characterization of Hyperphenylalaninemia Based on Expanded Neonatal Screening Data from 2023 to 2024 in the Russian Federation

    by Ekaterina E. Lotnik, Alena L. Chukhrova, Nina V. Ryadninskaya, Varvara A. Kadnikova, Ekaterina Y. Zakharova, Galina V. Baydakova, Andrey R. Osadchii, Inga V. Anisimova, Sergei V. Voronin, Sergey I. Kutsev, et al.

    Since January 2023, the Russian Federation has implemented expanded neonatal screening for 36 hereditary disorders, which has changed the diagnostic algorithm for hyperphenylalaninemia/phenylketonuria (HPA/PKU) by introducing tandem mass spectrometry (MS/MS) on the second day of life, followed by confirmatory biochemical and molecular testing in newborns at risk. We analyzed 1247 newborns aged 5–15 days with elevated phenylalanine levels (≥120 µmol/L) and a phenylalanine to tyrosine ratio of at least 1 detected during the first stage of screening using MS/MS. At the reference center, newborns underwent repeat biochemical testing and stepwise molecular analysis of HPA-associated genes. Two pathogenic variants in HPA-associated genes were identified in 538 newborns, including 534 newborns with biallelic pathogenic variants in PAH and 4 with BH4-deficient forms (PTS, QDPR). The incidence of molecularly confirmed HPA was 1:4518 newborns (95% CI: 1:4152–1:4925). The PAH variant spectrum was dominated by p.Arg408Trp (c.1222C>T) (33.4%). Genotype-based analysis indicated that 73 newborns (13.7%) were likely responsive to cofactor therapy, whereas 222 (41.6%) were potentially responsive. These findings define the molecular epidemiology of HPA in Russia and support early genetic stratification for diagnosis and treatment.

  • Open Access

    Clinical manifestations of monoclonal gammopathy of undetermined significance

    by Yu. V. Shatokhin, E. V. Burnasheva, A. A. Matsuga, I. A. Aboyan, I. V. Snezhko, E. V. Ryabikina, E. V. Degtereva, A. N. Zeltser, S. V. Mordanov, O. V. Morozova, et al.

    Monoclonal gammopathies are a heterogeneous group of diseases and conditions characterized by the proliferation of a single clone of plasma cells secreting immunoglobulins of homogeneous structure (M-protein). They occur with a frequency of 5-7 cases per 100, 000 population, predominantly in individuals over 50 years of age, especially those older than 70 years. The diagnosis of monoclonal gammopathy of undetermined significance (MGUS) is considered valid when monoclonal IgM paraprotein is detected in the blood at a concentration of less than 30 g/l, lymphoplasmacytic infiltration of the bone marrow is less than 10% of the examined trephine biopsy volume, and there are no signs of target organ damage that could be attributed to a lymphoproliferative disorder. Monoclonal immunoglobulin most often serves as a biomarker of clonal cell proliferation. In addition to plasma cell neoplasms (multiple myeloma, lymphoplasmacytic lymphoma, AL amyloidosis, and others), detection of paraprotein secretion reguires differential diagnosis with other lymphoproliferative disorders, myelodysplastic syndrome, Gaucher disease, systemic connective tissue diseases, liver disorders, sarcoidosis, Sjogren's syndrome, cold agglutinin disease and neurological conditions. B- cells dysfunction may also occur in various infectious and autoimmune diseases, immunodeficiency states, and solid tumors. The availability of serum protein electrophoresis with detection of an "M-gradient" within the compulsory medical insurance at the State Budgetary Institution of the Rostov Region "Consultative and Diagnostic Center "Zdorovye" in Rostov-on-Don" since 2019 has made it possible to assess the prevalence of this laboratory phenomenon and has increased physician awareness of the need for hematology consultation for such patients. The clinical course of MGUS is diverce: long-term benign paraproteinemia (>5 years) with possible transformation into a hematologic malignancy may occur, as well as manifestation of an oncohematological disease (AL amyloidosis), and, rarely, transient paraproteinemia associated with cytomegalovirus hepatitis. The manifestation of monoclonal gammopathies with a wide range of symptoms and syndromes necessitates a comprehensive diagnostic approach and interdisciplinary collaboration among physicians of various specialties.

  • Open Access

    Two Years of Expanded Newborn Screening in Russia: High-Throughput Detection of Inherited Metabolic Disorders by Tandem Mass Spectrometry with Next-Generation Sequencing Confirmation

    by Ekaterina Y. Zakharova, Galina V. Baydakova, Polina V. Baranova, Darya Y. Aleksandrova, Olga A. Shchagina, Yulia S. Itkis, Natalya V. Milovanova, Tatyana S. Nagornova, Olga N. Ivanova, Yana D. Nazarenko, et al.

    In 2023, the Russian Federation expanded its national newborn screening (NBS) program from 5 to 36 conditions, 29 of which are inherited metabolic diseases (IMDs). This study presents the first nationwide results and outcomes of the expanded NBS program. Between January 2023 and December 2024, dried blood spots from 2,466,615 newborns (98.53% of the birth cohort) were analyzed for IMDs using MS/MS. Screen-positive cases were referred to the national reference center for confirmatory testing, which included biochemical (MS/MS and GC-MS) and genetic analyses (NGS). A total of 41,728 neonates (1.69%) screened positive, of whom 37,733 underwent confirmatory testing. It resulted in 834 confirmed diagnoses of IMDs (1 in 2900 live births). Phenylketonuria was the most prevalent IMD (n = 538; 1 in 4600), followed by MCADD (n = 99; 1 in 25,000). Distinct regional and ethnic variations were observed, including a high prevalence of tyrosinemia type 1 in the Chechen Republic and MCADD in North Ossetia. The integration of NGS was essential for resolving complex cases, such as identifying heterozygous carriers and dual diagnoses. These findings underscore the program’s clinical utility, highlight unique epidemiological patterns, and identify challenges such as false positives and diagnostic complexities, which will guide future refinements.


  • Open Access

    13q Deletion Syndrome Presenting with Lymphopenia Detected Through Newborn Screening for Primary Immunodeficiencies

    by Irina Efimova, Anna Mukhina, Zhanna Markova, Sergey Mordanov, Irina Soprunova, Dmitry Pershin, Natalya Balinova, Yunna Petrusenko, Dmitry Meleshko, Rena Zinchenko, et al.

    The expanded newborn screening (NBS) program in the Russian Federation, launched in 2023, includes the detection of severe forms of T- and B-cell immunodeficiencies via TREC/KREC quantification. We report a rare case of a male infant having multiple congenital anomalies and lymphopenia identified through this program. Genetic testing revealed a 25.8 Mb terminal deletion spanning 13q31.2–qter, consistent with 13q deletion syndrome. Initial NBS revealed reduced TREC levels, prompting further evaluation. The patient exhibited a complex phenotype, including central nervous system malformation (alobar holoprosencephaly), severe congenital heart disease, renal hypoplasia, limb and genitourinary anomalies, and facial dysmorphism. Postnatal complications included pneumonia, pleuritis, and chylothorax. Flow cytometry demonstrated mild T- and B-cell lymphopenia. The genomic defect was characterized using long-read third-generation sequencing, enabling precise breakpoint identification and accurate mapping of deleted genes. The deletion was confirmed via subtelomeric FISH analysis. The patient died at 7 months of age due to the progression of underlying congenital anomalies and associated complications. Our findings broaden the clinical characterization of distal 13q deletion syndrome and demonstrate the value of long-read sequencing in structural chromosomal analysis. They further highlight the difficulties of caring for neonates having complex malformations and immune dysfunction. Given the potential for both primary and secondary immune disturbances, comprehensive immunological evaluation should be considered in patients having 13q deletion syndrome to improve diagnostic accuracy and inform appropriate clinical management.


  • Open Access

    Genotype Structure Alterations in 5q SMA Patients as a Result of the Newborn Screening Program Implementation in the Russian Federation

    by Maria A. Akhkiamova, Andrey V. Marakhonov, Victoria V. Zabnenkova, Kristina A. Mikhalchuk, Sergei V. Voronin, Sergey I. Kutsev, Victoria V. Musatova, Tatyana N. Kekeeva, Nina V. Ryadninskaya, Alena L. Chukhrova, et al.

    Since 2023, the Russian Federation (RF) has implemented an expanded newborn screening (NBS) program for 36 hereditary disorders, which now includes 5q spinal muscular atrophy (5q SMA). As a result of newborn screening for 5q SMA conducted in the RF during 2023–2024, 288 newborns with a homozygous deletion of exon 7 in the SMN1 gene were identified by molecular genetic methods. The overall observed incidence of 5q SMA was 1 in 8439 newborns, which does not significantly differ from the expected incidence of 1 in 7953 newborns, established by previous pilot screening projects (p > 0.05). A comparison of the genotypes of patients identified through selective and newborn screening showed statistically significant differences in the proportions of patients carrying two, three, and four or more copies of the SMN2 gene. These findings demonstrate that the NBS program is effective in detecting both individuals with more severe phenotypes, as expected, and those with milder forms of the disease.


  • Open Access

    Clinical observation of Erdheim–Chester disease: diagnostic difficulties, treatment options

    by A. A. Matsuga, I. A. Aboyan, G. P. Nistratov, V. V. Chernousov, S. I. Lemeshko, V. Yu. Katsiaev, O. V. Nistratova, E. V. Burnasheva, Yu. V. Shatokhin, I. V. Snezhko, et al.

    As is known, orphan diseases, which include histiocytosis, including Erdheim-Chester disease (ECD), occur under the guise of other diseases, which complicates timely diagnosis and treatment. The presence of various symptoms in patients with an unspecified diagnosis (weight loss, fever, chills, night sweats, malaise, shortness of breath, thirst, polyuria; pain in the muscles and joints, in the long tubular bones of the upper and lower extremities, in the lower back or abdomen due to kidney damage and/or retroperitoneal fibrosis; exophthalmos; rash, xanthomas; frequent infectious diseases; nystagmus, ataxia, dysarthria) requires doctors to be wary of BEC.The variety of symptoms is due to the involvement of many organs and systems (orbits, kidneys, skin, brain, including the pituitary gland; lungs; heart; blood vessels; tubular bones), which requires a thorough examination, including morphological verification of the pathological process. Histological examination of biopsy specimens for BEC is characterized by histiocytic infiltrates (so-called “foamy histiocytosis”) with signs of inflammation and the presence of Touton giant cells; Immunohistochemistry reveals positive staining of these giant cells for CD68 antigen and factor XIIIa. Bone scintigraphy reveals a pronounced symmetrical accumulation of radiopharmaceuticals in the affected bones; with radiography in places of ossalgia — significant symmetrical bilateral osteosclerosis of the periosteum; according to CT data - “hairy” kidneys, “lined” aorta as a result of infiltration with histiocytes. The BRAF V-600E gene mutation, detected in half of the cases, in combination with one or more clinical and morphological signs allows a correct diagnosis to be made. The treatment of this disease is quite complex due to the lack of multicenter international clinical studies due to the rare occurrence of this pathology. However, clinical studies are currently being conducted on the use of drugs of various groups in the treatment of BEC. There is no doubt that due to the rarity of the disease and the low awareness of doctors, our own clinical experience in managing such patients is of great interest.

  • Open Access

    Myelodysplastic syndrome: epidemiology, diagnostics and epigenetic disorders

    by P. V. Lipilkin, E. D. Kulaeva, A. N. Zeltser, S. V. Mordanov, Yu. V. Shatokhin, Ю. В. Шатохин

    Myelodysplastic syndrome is a group of myeloid neoplasms that arise from the action of damaging factors on hematopoietic stem cells, which are based on somatic mutations, which leads to the formation of clonal hematopoiesis. we know from epidemiological data that old age, male gender, and smoking are in themselves independent risk factors for myelodysplastic syndrome. These factors can potentiate the occurrence of mutations in the genome. In young people and children, myelodysplastic syndrome is a direct consequence of genetic abnormalities. There is an assumption that epigenetic regulatory genes are subject to frequent mutations. The chromatin of malignant cells acquires epigenetic abnormalities affecting tumor resistance, which explains their response to treatment with epigenetic drugs in combination with other therapies The appearance of new mutations potentiates hematopoiesis, which is accompanied by the shutdown of apoptosis and the transformation of myelodysplastic syndrome into acute myeloid leukemia. It is suggested that mutations in the genes of epigenetic regulators have functional effects on pluripotent hemopoietic stem cells. Epigenetic profiling of patients had a significant impact on understanding the molecular basis of etiology, pathogenesis, and patterns of transformation of myelodysplastic syndrome into acute myeloid leukemia, but it is not known which genes are the most clinically significant for their final use in laboratory diagnostics and targeted hypomethylating therapy. Despite the multitude of mutations in epigenetic regulators in myelodysplastic syndrome, the creation of prognostic models based on them requires a detailed study that includes not only analysis of the frequency of such mutations, but also the establishment of a relationship with clinically significant outcomes. The aim of this review is to study the prevalence of the mutational status of epigenetic regulation in patients with myelodysplastic syndrome.


  • The bacterial-viral microbiota of urine in healthy people

    by Y.L. Naboka, I.A. Gudima, S.V. Mordanov, K.S. Ibishev, A.V. Ilyash, M.I. Kogan

  • Open Access

    Possibilities of effective antitumor therapy of patients with chronic lymphocytic leukemia depending on the clinical and laboratory characteristics of the disease

    by Yu. V. Shatokhin, I. V. Snezhko, A. N. Zeltser, S. V. Mordanov, E. V. Burnasheva, L. P. Sizyakina, M. V. Kharitonova, E. V. Ryabikina, O. V. Gerasimova, G. Yu. Nagornaya, et al.

    Purpose: to determine the optimal therapy regimens in patients with CLL, depending on age, comorbidity, prognostic (genetic) factors, clinical picture. Materials and methods: analysis of case histories of 400 patients with CLL observed at the Rostov State Medical University, Ministry of Health of the Russian Federation from 2010 to 2020.Results: Immunochemotherapy according to the FCR and FCR-Lite regimens has shown high efficiency in primary and pre-treated patients in terms of the frequency of achieving complete and partial remissions and achieving progression-free survival. In untreated patients, complete remissions were obtained in 61 (71.7%), partial remissions - in 14 (16.4%); among pre-treated patients, respectively - 40 (20.5%) and 65 (33.8%).Conclusion: combination therapy according to the FCR and FCR-Lite regimens is an affordable and effective method of treatment for most patients with CLL. When the level of leukemic blood cells with 17p13 deletion is less than 15%, rituximab should be used in the first line of immunochemotherapy, and ibrutinib (imbruvica) in case of more than 15%. In mono-regimen, rituximab is effective in supportive - anti-relapse therapy and in the treatment of autoimmune complications.

  • Open Access

    Bacterial-viral Urine Microbiota in Uncomplicated Recurrent Infection of the Lower Urinary Tract: Results of Pilot Study

    by Ju. L. Naboka, M. I. Kogan, S. V. Mordanov, Kh. S. Ibishev, A. V. Ilyash, I. A. Gudima

    Introduction. Difficulties in the management and treatment of patients with uncomplicated recurrent lower urinary tract infection (LUTI) are largely because bacterial, viral and other components remain unexplored in the etiological structure of the disease.Purpose of the study. To study the urine bacterial-viral associations in uncomplicated recurrent infections of the lower urinary tract (LUT).Materials and methods. The study included 14 patients with uncomplicated recurrent infections of the LUT, the average age was 33.0 ± 4.7 years. The object of the study was the average portion of morning urine collected prior to the appointment of empirical antibiotic therapy. Urine was divided into 3 aliquots: 1 for general urine analysis, 2 for bacteriological examination, 3 for polymerase chain reaction (PCR).Results. Aerobic-anaerobic associations were found in urine in all cases. Enterobacteriaceae family representatives were discovered in 92.8% of cases; they were represented by E. coli (78.6%), Klebsiella spp. (14.2%), Proteus spp. (7.1%). Moreover, in one patient at the same time (7.1%) E. coli + Klebsiella spp was isolated from urine.The gram-positive microflora pattern consisted of 7 genera and / or species and in various combinations was found in all patients. The taxonomic structure of the gram-positive flora was represented by E. faecalis (64.3%), S. lentus (21.4%), Corynebacterium spp., S. warneri, E. faecium (14.3% each), S. epidermidis + E. coli was recorded in 4 (28.6%) women, E. faecalis + E. faecium + E. coli + Klebsiella spp. - in 1 (7.1%), E. faecalis + E. faecium + E. coli also in 1 (7.1%) patients.Non-clostridial anaerobic bacteria (NAB) were isolated from urine in all cases with Eubacterium spp dominating. (57.1%). The taxonomic structure of NAB was represented by 5 genera: Eubacterium spp., Peptostreptococcus spp., Peptococcus spp., Bifidobacterium spp., Propionibacterium spp.Viruses were detected in urine in 6 (42.9%) patients. Epstein-Barr virus (EBV) was detected in 4 (28.6%) of them, moreover, in 1 case, in association with human papillomavirus (HPV53), in two other cases (7.1% each), cytomegalovirus (CMV) was verified and human herpes simplex virus type 6 (HHV6), respectively.Conclusions. In patients with uncomplicated recurrent LUTI, viruses with a prevalence of EBV were verified in urine in 42.9% of cases (28.6%). Apparently, the treatment of this patients` cohort should be directed not only to the bacterial, but also the viral components of the urinary microbiota.